Lanthanum Carbonate for Hyperphosphatemia in Patients on Peritoneal Dialysis

Author:

Ohno Michiya1,Ohashi Hiroshige1,Oda Hiroshi2,Yokoyama Haruko2,Okada Miho2,Nagaya Mayu2,Izumi Kumiko1,Ito Hitomi1,Katoh Shuji1

Affiliation:

1. Division of Nephrology, Murakami Memorial Hospital, Asahi University, Gifu City, Gifu, Japan

2. Division of Nephrology, Gifu Prefectural Gifu General Hospital, Gifu City, Gifu, Japan

Abstract

Background The efficacy of the phosphate binder lanthanum carbonate has been demonstrated for hemodialysis patients, but no studies have focused on patients undergoing continuous ambulatory peritoneal dialysis (CAPD). We evaluated whether lanthanum carbonate could control phosphate levels in patients on CAPD. Methods In this 48-week open-label prospective study, 28 patients on CAPD with a phosphate level of 6 mg/dL or greater were given lanthanum carbonate titrated from 750 mg to 2250 mg daily to achieve a target serum phosphate level of less than 6 mg/dL. The primary efficacy endpoint was reduction of serum phosphate to less than 6 mg/dL. Serum levels of calcium and parathyroid hormone were also evaluated, as were the CaxP product and adverse effects. Results From week 4 to the end of the study at week 48, we observed a significant reduction of serum phosphate to 5.25 ± 0.97 mg/dL from 6.88 ± 1.06 mg/dL at study start ( p < 0.01). At the end of the study, 78.6% of participants had achieved the target of less than 6 mg/dL. Because no change of serum calcium occurred, the CaxP product declined significantly during the study. Intact parathyroid hormone declined gradually over the study period, but the change had not reached significance at the end of the study ( p = 0.11). The mean final dose of lanthanum carbonate was 946 mg daily. The only adverse effect reported was mild nausea in 1 patient. Conclusions Lanthanum carbonate is an effective phosphate binder that can control serum phosphate and CaxP product in CAPD patients with hyperphosphatemia. Lanthanum carbonate was well tolerated in our population.

Publisher

SAGE Publications

Subject

Nephrology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3